Primary Progressive Aphasias and Apraxia of Speech.


Journal

Continuum (Minneapolis, Minn.)
ISSN: 1538-6899
Titre abrégé: Continuum (Minneap Minn)
Pays: United States
ID NLM: 9509333

Informations de publication

Date de publication:
02 2019
Historique:
entrez: 2 2 2019
pubmed: 2 2 2019
medline: 26 7 2019
Statut: ppublish

Résumé

This article reviews two of the primary progressive aphasias (PPAs), disorders characterized by the early and predominant impairment of language, and primary progressive apraxia of speech, a degenerative motor speech disorder that is closely related to PPA. An outline of the history and controversy surrounding how these disorders are classified is provided before the article focuses on each disorder's clinical and imaging features. Over the past decade, the classification of degenerative speech and language disorders has been refined. Clinical, imaging, and pathologic evidence suggests that primary progressive apraxia of speech is a distinct degenerative disorder. Furthermore, multiple lines of evidence have highlighted issues with nonfluent/agrammatic variant PPA, which complicates the diagnosis, prognosis, and study of this disorder. Semantic variant PPA, while not without controversy, remains one of the most well-defined disorders, with good clinicopathologic correlation. Accurate classification and diagnosis of these degenerative speech and language disorders is crucial in clinical practice and ongoing research efforts. For nonfluent/agrammatic variant PPA, the authors suggest emphasizing agrammatism as the core inclusion criterion and taking care not to include patients with isolated or predominant apraxia of speech. Isolated apraxia of speech can be the manifestation of a degenerative disease and, based on the different prognosis, should be recognized as distinct from PPA. Finally, it is important to recognize that some patients with semantic dementia, despite sharing the same pathologic associations, may not meet criteria for PPA.

Identifiants

pubmed: 30707189
doi: 10.1212/CON.0000000000000699
pii: 00132979-201902000-00008
pmc: PMC6548538
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Case Reports Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Pagination

101-127

Subventions

Organisme : NIA NIH HHS
ID : R01 AG037491
Pays : United States
Organisme : NIDCD NIH HHS
ID : R01 DC014942
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS089757
Pays : United States

Références

Neurology. 2014 May 13;82(19):1729-35
pubmed: 24727315
Neurology. 2013 Jul 23;81(4):337-45
pubmed: 23803320
Brain. 2010 Jan;133(Pt 1):300-6
pubmed: 19805492
Brain. 2014 Oct;137(Pt 10):2783-95
pubmed: 25113789
J Neurol. 2015 Sep;262(9):2064-72
pubmed: 26076744
Am J Alzheimers Dis Other Demen. 2009 Oct-Nov;24(5):408-16
pubmed: 19700669
Neurol Clin. 2017 May;35(2):339-374
pubmed: 28410663
Brain Lang. 2018 Sep;184:54-65
pubmed: 29980072
Alzheimers Res Ther. 2016 Dec 5;8(1):52
pubmed: 27915998
Brain. 2016 Mar;139(Pt 3):986-98
pubmed: 26811253
Q J Exp Psychol. 1975 Nov;27(4):635-57
pubmed: 1197619
Am J Alzheimers Dis Other Demen. 2013 Sep;28(6):612-6
pubmed: 23838322
Continuum (Minneap Minn). 2019 Feb;25(1):34-51
pubmed: 30707186
J Int Neuropsychol Soc. 2015 Jul;21(6):429-35
pubmed: 26067425
Neurocase. 2016;22(1):55-9
pubmed: 25929342
Brain. 2013 Feb;136(Pt 2):601-18
pubmed: 23361063
J Speech Lang Hear Res. 2012 Oct;55(5):S1518-22
pubmed: 23033445
Brain. 2014 Jul;137(Pt 7):2065-76
pubmed: 24844729
Ann Neurol. 1987 Oct;22(4):533-4
pubmed: 3324947
Dement Geriatr Cogn Disord. 2015;39(5-6):281-6
pubmed: 25765123
Neurology. 2011 Mar 15;76(11):1006-14
pubmed: 21325651
J Alzheimers Dis. 2015;46(3):737-45
pubmed: 25854928
Lancet Neurol. 2012 Jun;11(6):545-55
pubmed: 22608668
Int Rev Psychiatry. 2013 Apr;25(2):130-7
pubmed: 23611343
Cortex. 2015 Aug;69:220-36
pubmed: 26103600
Neurobiol Aging. 2015 Mar;36(3):1245-52
pubmed: 25592958
Dement Geriatr Cogn Dis Extra. 2016 Sep 23;6(3):407-423
pubmed: 27790240
Neurology. 2013 Nov 19;81(21):1832-9
pubmed: 24142474
Lancet Neurol. 2007 Nov;6(11):1004-14
pubmed: 17945154
J Neuropsychol. 2019 Jun;13(2):214-239
pubmed: 29424041
J Neurol. 2018 Jun;265(6):1474-1490
pubmed: 29392464
Neurology. 2014 Apr 1;82(13):1119-26
pubmed: 24598709
Neurology. 2009 Nov 3;73(18):1443-50
pubmed: 19884571
Brain. 2012 May;135(Pt 5):1522-36
pubmed: 22382356
Neurology. 2017 Nov 28;89(22):2271-2279
pubmed: 29093069
Brain. 2012 May;135(Pt 5):1537-53
pubmed: 22525158
Neurology. 2013 Jul 30;81(5):456-62
pubmed: 23897873

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH